Tax & Penalty29 Sept 2026, 04:50 pm
Aurobindo Pharma Ordered to Pay ₹4.6 Cr in Tax Dispute
AI Summary
Aurobindo Pharma Ltd has received an order from the Appellate Joint Commissioner (ST), Hyderabad, confirming a demand for reversal of alleged excess Input Tax Credit (ITC) amounting to ₹2,56,44,999. This includes CGST of ₹81,04,008, SGST of ₹81,04,008, and IGST of ₹94,36,983. Additionally, the company is liable for interest of ₹1,78,19,409 and a penalty of ₹25,64,500, bringing the total disputed amount to ₹4,60,28,908. The order pertains to the financial year 2020-21 and relates to an alleged excess ITC claim in GSTR 3B compared to GSTR 2A. The company stated there is no material impact on its financials or operations and intends to file an appeal before the GST Appellate Tribunal.
Key Highlights
- Aurobindo Pharma faces ₹4.6 Cr tax demand including interest and penalty.
- Dispute concerns alleged excess ITC claim for FY 2020-21.
- Company confirms no material impact on financials or operations.
- Aurobindo Pharma plans to appeal the order at the GST Appellate Tribunal.
Price Impact
More from AUROPHARMA